Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.

JM

Joseph L. Mills MD

@jmills1955 · X

@JBraunMD @NealBarshes Rivaroxaban already has data to support use in PAD patients from the Compass Trial. Awaiting results of soon to be completed Voyager Trial #ComprehensiveVascularCare @VascularSVS @BCM_Surgery @JoshuaBeckmanMD @DrMarthaGulati @heatherlgornik @DrMarkCreager https://t.co/A7vghFHmLs

PC

Prof Derek Connolly

@DrDerekConnolly · X

@CotsCardiology @SABOURETCardio @SeguraCardio @RODRIGOVISCONT1 @hvanspall @FaustoHerediaDr @Echoraljpangio @AngoulvantD @giuseppe_ando @AnaCatarinaOrt @saia_francesco @gbiondizoccai @drgianma @FormigaFrancesc @Costa_F_8 @kaschenke @iamritu @AldecoBravo Compass ; Total mortality 3.4% in the rivaroxaban & aspirin group v 4.1% in the aspirin group HR 0.82; 0.71-0.96; P=0.01 Themis; Total mortality was 5.1% in the ticagrelor & aspirin group and 4.9% in the aspirin alone group https://t.co/Ck2i87JpuM https://t.co/clyCSNyTqQ

PC

Prof Derek Connolly

@DrDerekConnolly · X

@VLSorrellImages @CardiacJoshi @ASE360 this of course might be IN PART why the Atlas TIMI 51 https://t.co/DYGAOgNv0U and COMPASS studies https://t.co/iPx4M1F9HE both showed impressive reductions in embolic stroke & death. I'd suggest we need a trial in LV thrombus of VKA versus triple therapy of DAPT+RIVA 2.5mg bid

NC

Nephrology Journal Club

@NephJC · X

Here is the original #NEJM COMPASS trial if you need a quicker refresher. The original study, completed in 2017, was a cardiovascular outcomes trial (CVOT) with rivaroxaban & aspirin, alone or in combination. #NephJC https://t.co/lZjEDAhN3V

WA

World Stroke Academy

@WorldStrokeEd · X

#WeekendLecture #SecondaryPrevention

CM

cardio-met

@cardiomet_CE · X

18d) But . . . #DPI substantially reduced ischemic stroke recurrence compared with #aspirin alone in patients with stable coronary and peripheral artery #atherosclerosis in the #COMPASS trial

TP

tl;dr pharmacy

@tldrpharmacy · X

Check out tl;dr's first ever journal club with the COMPASS trial https://t.co/opX0AOuPnu

EV

Enzo Vásquez

@renal_enzo · X

@PUGGY__GIRL @morjcx @AcidoRinon COMPASS https://t.co/vqGTY99hSm

SB

Sakhi Bhansali

@DrSakhii · X

How frequently do you apply the COMPASS trial in your practice ? It showed that low dose rivaroxaban+aspirin was beneficial in reducing cardiovascular events, with a surprisingly low NNT for higher risk patients. #neurotwitter #MedTwitter #stroke

SB

Sakhi Bhansali

@DrSakhii · X

How frequently do you apply the COMPASS trail in your practice ? It showed that low dose rivaroxaban+aspirin was beneficial in reducing cardiovascular events, with a surprisingly low NNT for higher risk patients. #neurotwitter #MedTwitter #stroke

JR

Jesús Ramírez

@Jesusmra94 · X

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease | New England Journal of Medicine https://t.co/Gp7kkFLokJ

https://t.co/M2cdPElhGn

AO

Aleksa Osmi

@AleksaOsmis · X

RT @CiccaroneCenter:

N

nike

@wot_mikey · X

RT @CiccaroneCenter:

AL

Adnane Lahlou

@mac_eden · X

RT @CiccaroneCenter:

AM

Ala_Haddadin,MD,MHA

@ashaddadin11 · X

RT @CiccaroneCenter:

GL

Gigi Liu

@G2Disrupt · X

RT @CiccaroneCenter:

NP

Nidhi Patel

@NidhihpatelMD · X

RT @CiccaroneCenter:

RK

Richard Kollen

@nuclearball · X

RT @CiccaroneCenter:

JM

John Mannisi MD

@JMannisi · X

RT @CiccaroneCenter:

MM

Mohammad Keykhaei, MD, MPH

@m_keykhaei · X

RT @CiccaroneCenter:

SM

Seme Burka, MD

@SBurkaMD · X

RT @CiccaroneCenter:

T

9thGenTN

@9thGenTN · X

@AbbasiMuqtadir Since we are teaching per COMPASS in stable CAD you should use both an anti platelet & an anticoagulant (low dose rivaroxaban) https://t.co/ya6WsxSk95

How I AVOIDED a Stroke: My Atrial Fibrillation Story https://t.co/W9NqymRgrW via @YouTube

How I AVOIDED a Stroke: My Atrial Fibrillation Story https://t.co/NjSmzGsnTC via @YouTube https://t.co/zseLqYo9hY

TP

tl;dr pharmacy

@tldrpharmacy · X

Check out tl;dr's first ever journal club with the COMPASS trial https://t.co/rgMlVJlE3g

M

Mark

@headass_deadass · X

RT @NEJM: Original Article: Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease (COMPASS) https://t.co/ZUZPmv4SY0 #VisualA…

NC

Nephrology Journal Club

@NephJC · X

2/10 What did I miss? Many observational links exist between AKI/CKD and PPI use. PPI effect on adverse events was a prespecified outcome of the COMPASS trial - in this JASN publication, eGFR change is analyzed. https://t.co/lZjEDAhfen https://t.co/qhYIimSbqK

NC

Nephrology Journal Club

@NephJC · X

Here is the original #NEJM COMPASS trial if you need a quicker refresher. The original study, completed in 2017, was a cardiovascular outcomes trial (CVOT) with rivaroxaban & aspirin, alone or in combination. #NephJC https://t.co/lZjEDAhfen

T

thxxdtxddy

@thxxdtxddy · X

RT @NephJC: Here is the original #NEJM COMPASS trial if you need a quicker refresher. The original study, completed in 2017, was a cardiova…

AF

Anjana Gopal, MBBS, MD, DM Nephrology, FASN

@AnjanaGopal9 · X

RT @NephJC: Here is the original #NEJM COMPASS trial if you need a quicker refresher. The original study, completed in 2017, was a cardiova…

NC

Nephrology Journal Club

@NephJC · X

Here is the original #NEJM COMPASS trial if you need a quicker refresher. The original study, completed in 2017, was a cardiovascular outcomes trial (CVOT) with rivaroxaban & aspirin, alone or in combination. #NephJC https://t.co/lZjEDAhN3V

UA

Urbano Amaya

@urbanoamaya1708 · X

RT @MMJoseA1: EC - Enferm. vascular aterosclerótica: rivaroxabán 2,5 mg/12h + AAS mejor perfil CV y > efectos adversos vs AAS sola https://…

TP

tl;dr pharmacy

@tldrpharmacy · X

Check out tl;dr's first ever journal club with the COMPASS trial https://t.co/TRjwnJb8nB

CM

Chidambara .ML.

@chidambara09 · X

RT @knowmedge: A3: COMPASS Trial #ABIM #USMLE #NBME #Cardiology https://t.co/GRJOPFJGr3

NH

Nada Hassib

@NadaHassib1 · X

RT @knowmedge: A3: COMPASS Trial #ABIM #USMLE #NBME #Cardiology https://t.co/GRJOPFJGr3

K

knowmedge

@knowmedge · X

A3: COMPASS Trial #ABIM #USMLE #NBME #Cardiology https://t.co/GRJOPFJGr3 https://t.co/FLUW8bXyXW

SD

Søren Zöga Diederichsen

@SZDiederichsen · X

@WFMMD @Artesia_RCT @afnet_ev Did you think about a comparison w COMPASS https://t.co/O8413dtuo5 Also a (favorable?) tradeoff between thrombus and bleeding with low event rates, at least for stroke. But didn't pick up

SE

Shibata Masashi@GP×EBM

@EbmShibanyan · X

このRCTは2×3 factorical studyでして、もう1つの仮説検証の結果はNEJMに掲載されています。プロトコルはこちらのSupplementから参照できます。 https://t.co/P5sS9wVMgV

AP

Abdulla A. Damluji, MD, PhD

@DrDamluji · X

1️⃣5️⃣

TP

tl;dr pharmacy

@tldrpharmacy · X

Check out tl;dr's first ever journal club with the COMPASS trial https://t.co/0FQ5SdTMnL

SA

Suleman Aktaa

@SulemanAktaa · X

However, other studies have shown benefit from longer #DAPT / low dose #rivaroxaban in secondary prevention

TP

tl;dr pharmacy

@tldrpharmacy · X

RT @tldrpharmacy: Check out tl;dr's first ever journal club with the COMPASS trial https://t.co/wam7OWuoug

MG

Masuma Ghazanfar

@DrmasumaG · X

RT @abdulmannan74: Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease | NEJM https://t.co/BK1TmApFb2

B

BLOOD

@abdulmannan74 · X

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease | NEJM https://t.co/BK1TmApFb2

JK

Jonguk Kim

@DreffectKim · X

RT @NEJM: Original Article: Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease (COMPASS) https://t.co/ZUZPmv4SY0 #VisualA…

MG

Malik Ghannam

@GhannamMalik · X

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease | NEJM https://t.co/ZDas4qypda

名

名前

@akkiii0830 · X

https://t.co/rbfZh0tfQo Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

BD

Bertha Drummond

@berthadrummondn · X

RT @SIAC_cardio: #ESCCongress Rivaroxaban 2.5+AAS superior a AAS sola en prev.secundaria, aunque > tasa de sangrado. Estudio COMPASS https:…

NA

Nelson Alvarez

@nelson_alv · X

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease https://t.co/6qohfF6GFx

PH

peer_hh

@hh_peer · X

What about Rivaroxaban 10mg? The Compass trial (https://t.co/pS4IOU4skW) showed that rivaroxaban 5mg bid is as effective as Aspirin in stable CAD. And rivaroxaban 10mg is approved to prevent DVT after hip replacement. Is that a good compromise?

SP

Stefanos Zafeiropoulos, MD, MS, PhD

@Cardiaficionado · X

@GGiannakoulas https://t.co/aJ0SZ7LAHr INCLISIRAN trials-ORION https://t.co/LG4OMX6HG6 COMPASS trial - vascular dose rivaroxaban

CG

Carol Artigas Gomez

@cartigasg · X

RT @WorldStrokeEd: #WeekendLecture #SecondaryPrevention

YC

Yong Chuan Chee

@CyChuan · X

RT @WorldStrokeEd: #WeekendLecture #SecondaryPrevention

WA

World Stroke Academy

@WorldStrokeEd · X

#WeekendLecture #SecondaryPrevention

LA

Leticia bravo Aldecoa

@AldecoBravo · X

RT @DrDerekConnolly: @CotsCardiology @SABOURETCardio @SeguraCardio @RODRIGOVISCONT1 @hvanspall @FaustoHerediaDr @Echoraljpangio @Angoulvant…

PC

Prof Derek Connolly

@DrDerekConnolly · X

@CotsCardiology @SABOURETCardio @SeguraCardio @RODRIGOVISCONT1 @hvanspall @FaustoHerediaDr @Echoraljpangio @AngoulvantD @giuseppe_ando @AnaCatarinaOrt @saia_francesco @gbiondizoccai @drgianma @FormigaFrancesc @Costa_F_8 @kaschenke @iamritu @AldecoBravo Compass ; Total mortality 3.4% in the rivaroxaban & aspirin group v 4.1% in the aspirin group HR 0.82; 0.71-0.96; P=0.01 Themis; Total mortality was 5.1% in the ticagrelor & aspirin group and 4.9% in the aspirin alone group https://t.co/Ck2i87JpuM https://t.co/clyCSNyTqQ

GP

Gustavo Lenci Marques MD, PhD

@LenciMarques · X

2017: Outro ano difícil, escolhei o COMPASS. Esse foi o primeiro estudo a demonstrar uma medicação comparada ao AAS com benefício claro em pacientes com doença coronariana estável. Ref: https://t.co/XldbcOYF4O. *Menção Honrosa ao FOURIER que abriu portas para o uso dos iPCSK-9.

NA

Nelson Alvarez

@nelson_alv · X

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease https://t.co/IGiNwjhqPo Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major

EG

Ethical GmbH

@Ethicalgmbh · X

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease https://t.co/r6OFfDfGnj #clinicalresearch #clinicaltrials #endpointadjudication #electronichealthrecords #clinicalstudies #digitalsignatures #patientengagement #pharmacovigilance #eclinical https://t.co/Qn5wHVfEE9

AC

Andrés Olarte, M.D. MSc(c)

@andresolarte91 · X

RT @jsenior64: Finalmente el COMPASS trial demostró el beneficio de la combinación rivaroxaban +asa con reducción del desenlace primario y…

JS

Juan Senior

@jsenior64 · X

Finalmente el COMPASS trial demostró el beneficio de la combinación rivaroxaban +asa con reducción del desenlace primario y secundario, incluyendo muerte de cualquier causa, con aumento de la tasa de sangrado mayor, pero no fatal ni intracraneal. https://t.co/4csxDksPs3

AK

Ankur Kalra

@AnkurKalraMD · X

@RKTvascular @DLBHATTMD No; I actually meant rivaroxaban (Xarelto); see this @NEJM original research by Dr. @DLBHATTMD et al. https://t.co/8ryqcR8vRM

Nب

Najdat Bazarbashi نجدت بازارباشي

@NajdatB1 · X

@abdalllla @M7md_K @fessdoc @ftamimi11 Good catch. Here you go https://t.co/l5LqllriOd

PC

Prof Derek Connolly

@DrDerekConnolly · X

@ncurzen there was no difference in total mortality of ASA v P2Y12i in Compass we showed a total mortality benefit [HR=0.82] of ASA+baby dose RIVA over ASA but the authors gloss over that I'd say death is more important than bleeding https://t.co/iPx4M1F9HE [https://t.co/DYGAOgNv0U] https://t.co/75U3FsShHh

TJ

Tom Johnson

@twj1974 · X

@admit_medics @KirstyChallen @RCEM_VP Compass trial https://t.co/BXVxi8mh4G demonstrated benefit in high CV risk patients (not on DAPT though). IT solutions esp. connecting care in SouthWest overcomes issue of patient’s forgetting their prescriptions @DataDonuts @chrisbourdeaux @sarahhudsonuk

BW

Binod Wagle

@binodbinodwagle · X

#UMKCRCT; ischemic stoke significantly less in NOAC +ASA vs NOAC, but hemorrhage higher in NOAC alone vs both(not statistically significant) vs ASA (clinically +statistically significant) https://t.co/pg762UkpNG

名

名前

@akkiii0830 · X

https://t.co/ry0hsD3095 Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease 似たとこ、その2

CE

COR etc.

@cor_etc · X

RT @JWatch: The COMPASS trial: This week's @NEJM #VisualAbstract gives a recap. Read the full Original Article: https://t.co/uAjByYItsh htt…

I

#independència

@rosadira · X

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease | NEJM https://t.co/wYMnTNdwmH

Jǟ

jedicath աǟզǟʀ.ǟɦʍɛɖ

@jedicath · X

RT @DrDerekConnolly: @jedicath @EilidhPinkChic @stefan_harb @mmamas1973 there are no RCTs but of course this might have been one of the way…

PC

Prof Derek Connolly

@DrDerekConnolly · X

@jedicath @EilidhPinkChic @stefan_harb @mmamas1973 there are no RCTs but of course this might have been one of the ways that combination therapy [of aspirin and rivaroxaban] worked in the Compass study to reduce stroke by 42% https://t.co/iPx4M1F9HE

名

名前

@akkiii0830 · X

https://t.co/ry0hsD3095

PC

Prof Derek Connolly

@DrDerekConnolly · X

@DocSavageTJU @mmamas1973 @DrMarthaGulati @GreggWStone @Drroxmehran @rwyeh @SVRaoMD @DLBHATTMD @mirvatalasnag @SABOURETCardio @sbrugaletta @HeartOTXHeartMD @willsuh76 @djc795 @sloaneguy @fischman_david why are you not considering the Atlas TIMI 51 / Compass protocol of ASA/P2Y12/Baby dose rivaroxaban Mike? Don't mortality benefits trump bleeding? @CMichaelGibson @DrSoniaAnand1 https://t.co/dj5gSy4AsE https://t.co/yEZbPagOuD

湘臨

湘南厚木病院 臨床研修センター

@ShonanAtsugi · X

https://t.co/D4UJnygPi7 ちなみにこの研究と一緒にRCT組んでます。お得な研究ですね。

AD

Ava Star M.D.

@AvaStarMD · X

RT @jmills1955: @JBraunMD @NealBarshes Rivaroxaban already has data to support use in PAD patients from the Compass Trial. Awaiting results…

DG

Dr. Martha Gulati ♥️

@DrMarthaGulati · X

RT @jmills1955: @JBraunMD @NealBarshes Rivaroxaban already has data to support use in PAD patients from the Compass Trial. Awaiting results…

JM

Joseph L. Mills MD

@jmills1955 · X

@JBraunMD @NealBarshes Rivaroxaban already has data to support use in PAD patients from the Compass Trial. Awaiting results of soon to be completed Voyager Trial #ComprehensiveVascularCare @VascularSVS @BCM_Surgery @JoshuaBeckmanMD @DrMarthaGulati @heatherlgornik @DrMarkCreager https://t.co/A7vghFHmLs

名

名前

@akkiii0830 · X

ごく少量のリバーロキサバン（2.5mg×2）についても記載あり（使用対象は心房細動ではない）。 臨床試験が終わって結果が出ていたことを初めて知った。しかもかなり前。 https://t.co/EV3iHv3eza

AC

Aaysha Cader

@aayshacader · X

RT @mirvatalasnag: #ESCCongress Was there any reference in guidelines to using Rivaroxaban for stable CAD? #COMPASS https://t.co/I32QNF1…

MI

MIЯVΛƬ #IC ༄ ｡°

@mirvatalasnag · X

#ESCCongress Was there any reference in guidelines to using Rivaroxaban for stable CAD? #COMPASS https://t.co/I32QNF1S9K @Hragy @DrAfzalSohaib @SilCastelletti @escardio https://t.co/fwRSH1Yo4t

SN

Syed Shahrul Naz

@drshahrul80 · X

RT @DrDerekConnolly: @VLSorrellImages @CardiacJoshi @ASE360 this of course might be IN PART why the Atlas TIMI 51 https://t.co/DYGAOgNv0U a…

DO

Doaa El Okda

@OkdaDr · X

RT @DrDerekConnolly: @VLSorrellImages @CardiacJoshi @ASE360 this of course might be IN PART why the Atlas TIMI 51 https://t.co/DYGAOgNv0U a…

PC

Prof Derek Connolly

@DrDerekConnolly · X

@VLSorrellImages @CardiacJoshi @ASE360 this of course might be IN PART why the Atlas TIMI 51 https://t.co/DYGAOgNv0U and COMPASS studies https://t.co/iPx4M1F9HE both showed impressive reductions in embolic stroke & death. I'd suggest we need a trial in LV thrombus of VKA versus triple therapy of DAPT+RIVA 2.5mg bid

D

DrVeins

@drgarcivenas · X

@merolengo1972 @doctormacias https://t.co/QFIO6DLuT9

MB

Merry Doerning, PharmD, BCEMP

@merrysanders19 · X

If you see rivaroxaban 2.5 mg BID on your patients home list, it may not be an error! It was recently (Oct ‘18) approved for CAD/PAD and was shown to reduce MACE in addition to aspirin. #inservice Compass TRIAL: https://t.co/sBjEHfTfuI.

TT

The TRACK Trial

@TRACK_trial · X

@abdelhamed012 @Badves @georgeinstitute @DrSoniaAnand1 @PHRIresearch Good question. The TRACK trial is based on the COMPASS trial, which showed beneficial outcomes with very low dose rivaroxaban even in CKD patients. https://t.co/hidJYw7dMQ and https://t.co/WGvTjcVG7t

AB

Adam Barelski

@ABarelski_MD · X

COMPASS trial showed decreased MACE in patients with stable ischemic heart disease in pts given low-dose rivarox + ASA vs ASA or rivarox alone. Increased risk of bleeding and trend toward decreased mortality. Anyone using rivarox for this indication? https://t.co/mopY2W52UO

PC

Prof Derek Connolly

@DrDerekConnolly · X

@karthikbala24 @mmamas1973 @jmahmed @SVRaoMD @nolanjimradial @BoopathyCardio https://t.co/iPx4M1F9HE

Practice-changing? Seems maybe not. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease — NEJM http://www.nejm.org/doi/full/10.1056/NEJMoa1709118